Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ADXN
- Price
- 7.29
- Stock movement up
- +0.42 (6.04%)
- Company name
- Addex Therapeutics Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 7.79M
- Ent value
- 5.54M
- Price/Sales
- 13.97
- Price/Book
- 0.70
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 1.44
- Forward P/E
- -
- PEG
- -
- EPS growth
- -55.85%
- 1 year return
- -73.26%
- 3 year return
- -58.12%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ADXN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 1.44 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 13.97 |
| Price to Book | 0.70 |
| EV to Sales | 9.95 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.07M |
| EPS (TTM) | 35.94 |
| FCF per share (TTM) | -29.29 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 557.48K |
| Gross profit (TTM) | 404.11K |
| Operating income (TTM) | -4.99M |
| Net income (TTM) | 5.40M |
| EPS (TTM) | 35.94 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 72.49% |
| Operating margin (TTM) | -895.49% |
| Profit margin (TTM) | 969.49% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 3.35M |
| Net receivables | 516.51K |
| Total current assets | 4.07M |
| Goodwill | 0.00 |
| Intangible assets | 21.68K |
| Property, plant and equipment | 0.00 |
| Total assets | 12.17M |
| Accounts payable | 325.78K |
| Short/Current long term debt | 43.77K |
| Total current liabilities | 887.56K |
| Total liabilities | 1.11M |
| Shareholder's equity | 11.06M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -5.97M |
| Capital expenditures (TTM) | 3.68K |
| Free cash flow (TTM) | -4.41M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 48.86% |
| Return on Assets | 44.42% |
| Return on Invested Capital | 48.83% |
| Cash Return on Invested Capital | -39.80% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.00 |
| Daily high | 7.57 |
| Daily low | 7.00 |
| Daily Volume | 7K |
| All-time high | 483.80 |
| 1y analyst estimate | 30.00 |
| Beta | 1.87 |
| EPS (TTM) | 35.94 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ADXN | S&P500 | |
| Current price drop from All-time high | -98.49% | -12.89% |
| Highest price drop | -98.94% | -56.47% |
| Date of highest drop | 18 Dec 2023 | 9 Mar 2009 |
| Avg drop from high | -80.14% | -11.07% |
| Avg time to new high | 415 days | 12 days |
| Max time to new high | 1079 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
7.79M
Marketcap category
Small-cap
Description
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot"Marie"Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Employees
23
Investor relations
-
SEC filings
CEO
Timothy Dyer
Country
USA
City
Geneva
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page